The amount of dna combined with tp53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and vegfr-tkis

HIGHLIGHTS

  • who: Marzia Del Re from the of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy have published the article: The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs, in the Journal: (JOURNAL)
  • what: This study shows that cfDNA and TP53 are potential predictive biomarkers of response in mccRCC to be further explored in larger and/or prospective studies. The authors aimed to enhance the understanding of the genomic context of mccRCC and the predictive/prognostic value of . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?